The Journal of Pediatrics
Volume 152, Issue 4 , Pages 467-470 , April 2008

Is it Possible to Protect Pediatric Research Subjects without Blocking Appropriate Research?

  • David Wendler, PhD

      Affiliations

    • Corresponding Author InformationReprint requests: David Wendler, Department of Bioethics, National Institutes of Health, Building 10, Room 1C118, Bethesda, MD 20892.

Received 18 July 2007 ,Revised 13 August 2007 ,Accepted 12 September 2007.

References 

  1. Regulations on new therapy and human experimentation. Reprinted in: International Digest of Health Legislation. 1980;31:408–411
  2. Vollmann J, Winau R. Informed consent in human experimentation before the Nuremberg code. BMJ. 1996;313:1445–1449
  3. The Nuremberg Code. JAMA. 1996;276:1691
  4. Kauffman RE. Clinical trials in children: problems and pitfalls. Paediatr Drugs. 2000;2:411–418
  5. Caldwell PHY, Murphy SB, Butow PH, Craig JC. Clinical trials in children. Lancet. 2004;364:803–811
  6. Roberts R, Rodriquez W, Murphy D, Crescenzi T. Pediatric drug labeling: improving the safety and efficacy of pediatric therapies. JAMA. 2003;290:905–911
  7. Berlin I, Gorelick D. The French law on “protection of persons undergoing biomedical research”; implications for the U.S. J Law Med Ethics. 2002;31:434–441
  8. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Good clinical practice: consolidated guidance. Published in Federal Register. 1997;62:25692;May 9
  9. US Department of Health and Human Services. Code of Federal Regulations. 45 CFR 46, subpart D.
  10. US Food and Drug Administration. Code of Federal Regulations. Title 21, 50.25. Vol 1, revised April 1, 2005.
  11. Kopelman LM. Minimal risk as an international ethical standard in research. J Med Philos. 2004;29:351–378
  12. Ross LF, Nelson RM. Pediatric research and the federal minimal risk standard. JAMA. 2006;295:759–760
  13. Resnik DB. Eliminating the daily risks standard from the definition of minimal risk. J Med Ethics. 2005;31:35–38
  14. Wendler D, Glantz L. A new standard for assessing the risks of pediatric research: pro and con. J Pediatr. 2007;150:579–582
  15. Kummar S, Kinders R, Rubinstein L, Parchment RE, Murgo AJ, Collins J, et al. Compressing drug development timelines in oncology using phase “0” trials. Nat Rev Cancer. 2007;7:131–139
  16. Freedman B. Equipoise and the ethics of clinical research. N Engl J Med. 1987;317:141–145
  17. Eddy DM. Health system reform (Will controlling costs require rationing services?). JAMA. 1994;272:324–328
  18. Daniels N. Just health care. New York, N.Y: Cambridge University Press; 1995;
  19. Institute of Medicine. Ethical conduct of clinical research involving children. In:  Field MJ,  Berman RE editor. Washington, DC: The National Academies Press; 2005;

 This work was completed as part of the author’s official duties as an employee of the NIH Clinical Center. The opinions expressed are the author’s own. They do not represent any position or policy of the National Institutes of Health, Public Health Service, or Department of Health and Human Services.

PII: S0022-3476(07)00887-6

doi: 10.1016/j.jpeds.2007.09.027

The Journal of Pediatrics
Volume 152, Issue 4 , Pages 467-470 , April 2008

Article Tools

* Image Usage & Resolution